Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment
Lot-specific COA documentation for every compound referenced here is available in our Certificates of Analysis Library, and additional sourcing questions are covered on our FAQ page
The medication also slows digestion to prevent post-meal glucose spikes
Can I skip dinner on GLP-1 medications
:max_bytes(150000):strip_icc()/Health-GettyImages-2112991427-c2c4d692054b4ff6933f01fc6c5be06c.jpg)
Gently and slowly depress the plunger, allowing the water to run down the side of the glass and pool at the bottom
US$ 21.52
US$ 27.22
US$ 20.37
US$ 26.70
US$ 22.80
